| Literature DB >> 35340975 |
K Shankar1, Srinivasan Rangalakshmi1, D Priyanka1, P Kailash1, Vijaykumar Kadlimatti Deepak1.
Abstract
Background and Aims: In percutaneous nephrolithotomy (PCNL), distension of renal capsule, pelvicalyceal system and nephrostomy tube causes intense postoperative pain. The present study was done to compare the efficacy of peritubal infiltration of Ropivacaine with Dexmedetomidine and ultrasound guided single level T10 paravertebral block for post-operative analgesia in patients undergoing PCNL. Material andEntities:
Keywords: Paravertebral block; percutaneous nephrolithotomy; peritubal infiltration; post-operative analgesia
Year: 2022 PMID: 35340975 PMCID: PMC8944380 DOI: 10.4103/joacp.JOACP_64_20
Source DB: PubMed Journal: J Anaesthesiol Clin Pharmacol ISSN: 0970-9185
Figure 1Comparison of age groups in all three groups
Figure 2Gender distribution between the groups
Demographic Characteristics
| Variables | Group PV | Group PT | Group C | Total |
|---|---|---|---|---|
| Age in years | 39.85±5.65 | 40.05±5.52 | 39.60±5.47 | 39.83±5.46 |
| Gender (Male/Female) | 10/10 | 11/9 | 10/10 | |
| Weight (kg) | 52.70±3.16 | 53.10±4.20 | 52.05±3.85 | 52.62±3.72 |
| Height (cm) | 152.10±4.97 | 151.70±5.11 | 152.00±4.61 | 151.93±4.82 |
Duration of Surgery and Anaesthesia (in minutes)
| Variables | Group PV | Group PT | Group C | Total | P |
|---|---|---|---|---|---|
| Duration of Anesthesia | 126.30±17.86 | 124.40±15.59 | 124.80±14.06 | 125.17±15.66 | 0.924 |
| Duration of Surgery | 98.15±19.35 | 102.65±18.41 | 98.70±17.71 | 99.83±18.30 | 0.705 |
VAS Score at Rest
| VAS at Rest | Group Wise Significance | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Group PV | Group PT | Group C | Group PV vs Group PT | Group PV vs Group C | Group PT vs Group C | |
| 1 h | 1.70±0.47 | 1.45±0.60 | 2.80±1.01 | 0.528 | <0.001 | <0.001 |
| 2 h | 1.80±0.41 | 1.55±0.69 | 2.65±1.09 | 0.572 | <0.001 | <0.001 |
| 4 h | 2.05±0.22 | 2.2±0.52 | 3.00±1.17 | 0.803 | 0.004 | 0.001 |
| 8 h | 2.75±0.79 | 2.45±1.00 | 3.70±0.86 | 0.537 | <0.001 | 0.004 |
| 12 h | 2.25±0.44 | 2.85±0.81 | 5.75±0.64 | 0.014 | <0.001 | <0.001 |
| 24 h | 2.40±0.60 | 3.95±1.05 | 6.05±0.94 | <0.001 | <0.001 | <0.001 |
Significant (P<0.05), Highly significant (P<0.001)
Dynamic VAS
| Dynamic VAS | Group Wise Significance | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Group PV | Group PT | Group C | Group PV vs Group PT | Group PV vs Group C | Group PT vs Group C | |
| 1 h | 1.80±0.41 | 1.55±0.69 | 4.15±1.09 | 0.572 | <0.001 | <0.001 |
| 2 h | 2.35±0.75 | 2.15±0.88 | 3.80±1.11 | 0.772 | <0.001 | <0.001 |
| 4 h | 2.70±0.57 | 2.60±0.99 | 4.25±1.65 | 0.960 | <0.001 | <0.001 |
| 8 h | 3.15±1.31 | 4.50±1.36 | 6.55±1.15 | 0.004 | <0.001 | <0.001 |
| 12 h | 3.40±0.60 | 4.45±1.36 | 6.95±1.00 | 0.006 | <0.001 | <0.001 |
| 24 h | 2.90±0.79 | 5.70±1.72 | 7.30±0.86 | <0.001 | <0.001 | <0.001 |
Significant (P<0.05), Highly significant (P<0.001)
Tramadol Requirement (mg)
| Tramadol Consumption | Group PV (n=20) | Group PT (n=20) | Group C (n=20) | Total (n=60) | P |
|---|---|---|---|---|---|
| 0-4 h | 63.33±10.41 | 55.00±8.66 | 56.25±7.76 | 56.92±8.13 | 0.352 |
| 4-8 h | 63.33±10.41 | 58.13±8.89 | 56.25±7.76 | 57.42±8.25 | 0.381 |
| 8-24 h | 75,00±38.19 | 105.25±28.90 | 138.00±34.65 | 112.33±40.12 | <0.001 |
| Total 24 h | 113.00±98.88 | 133.50±61.02 | 250.54±45.07 | 176.20±88.55 | <0.001 |
Highly significant (P<0.001)
Figure 3Comparison of tramadol consumption in all three groups
Figure 4Comparison of sedation scores among the study groups
Figure 5Comparison of heart rate among the study groups
Figure 6Comparison of Mean arterial pressure among the study groups
Tramadol Related Side Effects
| Opioid related side effects | Group PV (n=20) | Group PT (n=20) | Group C (n=20) | Total (n=60) | P |
|---|---|---|---|---|---|
| Nausea | 3 (15%) | 8 (40%) | 12 (60%) | 23 (38.3%) | 0.014 |
| Vomiting | 1 (5%) | 3 (15%) | 4 (20%) | 8 (13.3%) | 0.505 |
| Itching | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000 |
| Constipation | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000 |
| Urinary retention | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1.000 |
| Additional analgesic | 3 (15%) | 4 (20%) | 13 (65%) | 20 (33.3%) | 0.001 |
Significant (P<0.05), Highly significant (P<0.001)
Figure 7Comparison of opioid related side effects among the study groups